Total Payments
$1.3M
2024 Payments
$31,067
Companies
28
Transactions
959
Medicare Patients
10,749
Medicare Billing
$4.0M
Payment Breakdown by Category
Other$866,823 (67.9%)
Consulting$290,508 (22.7%)
Travel$91,224 (7.1%)
Food & Beverage$18,945 (1.5%)
Research$9,369 (0.7%)
Education$605.30 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $824,363 | 321 | 64.5% |
| Consulting Fee | $290,508 | 103 | 22.7% |
| Travel and Lodging | $91,224 | 224 | 7.1% |
| Honoraria | $29,650 | 9 | 2.3% |
| Food and Beverage | $18,945 | 278 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $12,810 | 7 | 1.0% |
| Unspecified | $9,369 | 5 | 0.7% |
| Education | $605.30 | 12 | 0.0% |
Payments by Type
General
$1.3M
954 transactions
Research
$9,369
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $246,025 | 175 | $0 (2024) |
| Exelixis Inc. | $219,223 | 139 | $0 (2024) |
| Astellas Pharma US Inc | $127,935 | 108 | $0 (2024) |
| Eisai Inc. | $116,644 | 98 | $0 (2024) |
| EMD Serono, Inc. | $113,042 | 75 | $0 (2023) |
| Janssen Biotech, Inc. | $103,012 | 76 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $77,135 | 59 | $0 (2023) |
| Merck Sharp & Dohme LLC | $54,746 | 34 | $0 (2023) |
| Seagen Inc. | $53,134 | 44 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $50,364 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,067 | 26 | Eisai Inc. ($17,992) |
| 2023 | $119,734 | 139 | Merck Sharp & Dohme LLC ($23,257) |
| 2022 | $169,006 | 124 | EMD Serono, Inc. ($30,100) |
| 2021 | $181,604 | 114 | Eisai Inc. ($29,998) |
| 2020 | $175,272 | 114 | PFIZER INC. ($36,261) |
| 2019 | $244,858 | 170 | PFIZER INC. ($60,323) |
| 2018 | $196,441 | 139 | PFIZER INC. ($60,975) |
| 2017 | $159,492 | 133 | PFIZER INC. ($65,952) |
All Payment Transactions
959 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $571.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,280.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $740.00 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $4,620.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $102.33 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/22/2024 | Exelixis Inc. | CABOMETYX (Drug) | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/25/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Aveo Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $134.87 | General |
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $44.25 | General |
| 05/31/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Oncology | ||||||
| 05/29/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $3,925.00 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: Oncology | ||||||
| 05/07/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 04/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $40.01 | General |
| Category: Oncology | ||||||
| 04/16/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $41.67 | General |
| Category: Oncology | ||||||
| 03/19/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: ONCOLOGY | ||||||
| 01/29/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $40.29 | General |
| 01/16/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: Oncology | ||||||
| 01/12/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $14,026.91 | General |
| Category: Oncology | ||||||
| 01/12/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,800 | 3 |
| A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA | F. Hoffmann-La Roche AG | $812.50 | 1 |
| A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | F. Hoffmann-La Roche AG | $756.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,351 | 55,672 | $5.3M | $1.0M |
| 2022 | 58 | 2,642 | 64,610 | $4.7M | $856,053 |
| 2021 | 55 | 2,909 | 59,118 | $5.1M | $979,497 |
| 2020 | 55 | 2,847 | 63,196 | $5.6M | $1.1M |
Total Patients
10,749
Total Services
242,596
Medicare Billing
$4.0M
Procedure Codes
218
All Medicare Procedures & Services
218 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 47 | 16,600 | $2.3M | $710,102 | 31.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 501 | $184,368 | $48,917 | 26.5% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 11 | 83 | $127,512 | $47,571 | 37.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 38 | 354 | $1.3M | $45,919 | 3.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,220 | $145,200 | $37,247 | 25.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 174 | 301 | $212,807 | $30,814 | 14.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 11 | $52,822 | $12,983 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 76 | 164 | $41,000 | $10,069 | 24.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 115 | 372 | $58,404 | $8,589 | 14.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 164 | 714 | $45,696 | $7,325 | 16.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 31 | 33 | $35,211 | $5,796 | 16.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 157 | 648 | $12,960 | $5,410 | 41.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $22,688 | $5,405 | 23.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 163 | 691 | $24,876 | $5,218 | 21.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 49 | 88 | $30,272 | $4,536 | 15.0% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 81 | 256 | $24,064 | $4,527 | 18.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 17 | 33 | $16,500 | $4,456 | 27.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 106 | 271 | $29,268 | $3,322 | 11.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 41 | 114 | $16,530 | $2,922 | 17.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 59 | $18,467 | $2,885 | 15.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $8,432 | $2,410 | 28.6% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 39 | 41 | $33,661 | $2,044 | 6.1% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 14 | 24 | $12,000 | $1,940 | 16.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 31 | $6,541 | $1,808 | 27.6% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 51 | 12,900 | $64,500 | $1,643 | 2.5% |
About Thomas Hutson, DO,PHARMD
Thomas Hutson, DO,PHARMD is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609819069.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Thomas Hutson, DO,PHARMD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $31,067 received in 2024. These payments were reported across 959 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($824,363).
As a Medicare-enrolled provider, Hutson has provided services to 10,749 Medicare beneficiaries, totaling 242,596 services with total Medicare billing of $4.0M. Data is available for 4 years (2020–2023), covering 218 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Dallas, TX
- Active Since 06/14/2006
- Last Updated 09/01/2011
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1609819069
Products in Payments
- Cabometyx (Drug) $171,784
- XTANDI (Drug) $150,394
- Lenvima (Drug) $116,536
- Bavencio (Drug) $75,806
- OPDIVO (Biological) $68,946
- SUTENT (Drug) $68,688
- INLYTA (Drug) $64,204
- Erleada (Drug) $55,076
- ERLEADA (Drug) $50,389
- LYNPARZA (Drug) $50,335
- CABOMETYX (Drug) $47,286
- PADCEV (Biological) $46,575
- Xtandi (Drug) $36,805
- BAVENCIO (Drug) $33,037
- FOTIVDA (Drug) $32,960
- Trodelvy (Drug) $22,894
- Bavencio (Biological) $17,241
- KEYTRUDA (Biological) $14,765
- PROVENGE (Drug) $10,640
- Rubraca (Drug) $9,841
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262
Dr. Stephen Jones, Md, MD
Medical Oncology — Payments: $221,960
Medical Oncology $221,960